Brett King is a Dermatology physician affiliated with Fairfield University. OpenAlex indexes 278 publications with 11,749 citations (h-index 61); ClinicalTrials.gov lists 7 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Dermatology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Follicular Revival in Fibrosing Alopecia: Evaluating Use of Micro-needling
Sponsor: Yale University
- Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling
Sponsor: Yale University
- Evaluation of AMG 714 for Vitiligo
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
116 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
116 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
50.2%Arteriolar Vasodilator31.3%Minoxidil100%Part D≥63 patientsAldosterone antagonist (MRA)18.9%Spironolactone100%Part D≥38 patientsAntiparasitic
9.9%Antimalarial9.9%Hydroxychloroquine Sulfate100%Part D≥15 patientsDermatology
9.6%Corticosteroid5.1%Triamcinolone Acetonide100%Part D≥17 patientsInterleukin-4 Receptor alpha Antagonist4.4%Dupixent Syringe100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
American Journal of Clinical Dermatology
2023 - Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial
Journal of the American Academy of Dermatology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Hywel C Williams
University of Nottingham
Mohsen Afarideh, MD, MPH
Mayo Clinic
Brigitte Dréno
Centre National de la Recherche Scientifique
Giovanni Damiani
University of Milan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”